Ixabepilone in Treating Young Patients With Refractory Solid Tumors

NCT ID: NCT00331643

Last Updated: 2014-11-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-04-30
• Study Completion Date: 2009-06-30

Brief Summary

This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the response rate to ixabepilone in various strata of recurrent solid malignant tumors of childhood and young adulthood, including all of the following: Embryonal or alveolar rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma/peripheral neuroectodermal tumor, synovial sarcoma or malignant peripheral nerve sheath tumor, Wilms' tumor, and neuroblastoma.

II. Determine the time to progression for each tumor stratum. III. Prospectively evaluate the feasibility and utility of automated volumetric tumor measurement in patients with measurable pulmonary metastases, and descriptively compare volumetric measurements to 1-dimensional (RECIST criteria) and 2-dimensional (WHO criteria) measurements.

IV. Define and describe the toxicities of ixabepilone.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (Ewing's sarcoma/ peripheral neuroectodermal tumor vs osteosarcoma vs alveolar or embryonal rhabdomyosarcoma vs Wilms' tumor vs neuroblastoma vs synovial sarcoma/malignant peripheral nerve sheath tumor).

Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed up every year for 5 years.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Conditions

Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Alveolar Childhood Rhabdomyosarcoma; Childhood Synovial Sarcoma; Embryonal Childhood Rhabdomyosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (ixabepilone)

Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.

Group Type: EXPERIMENTAL

ixabepilone

Intervention Type: DRUG

Given IV

Interventions

ixabepilone

Given IV

Intervention Type: DRUG

Other Intervention Names

BMS-247550; epothilone B lactam; Ixempra

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed diagnosis (at original diagnosis or recurrence) of 1 of the following:

• Embryonal or alveolar rhabdomyosarcoma
• Osteosarcoma*
• Ewing's sarcoma /peripheral neuroectodermal tumor*
• Synovial sarcoma or malignant peripheral nerve sheath tumor*
• Wilms' tumor*

• Age ≤ 21 years at original diagnosis
• Neuroblastoma

• Age ≤ 21 years at original diagnosis
• Clinically or radiographically measurable or evaluable (by iodine I 123 metaiodobenzoguanine sulfate [^123I-MIBG] or bone scan [evaluable tumors must be positive at ≥ 1 site])

• If lesion was previously irradiated, a biopsy must be performed ≥ 6 weeks after completion of radiotherapy and viable neuroblastoma must be demonstrated
• No elevated urinary catecholamines and/or bone marrow evidence of tumor with measurable disease clinically or by imaging modalities (CT scan, MRI, ^123I-MIBG, or bone scan)
• Refractory or recurrent disease with no known curative treatment options
• ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100% (patients > 16 years of age) OR Lansky PS 50-100% (patients ≤ 16 years)
• Life expectancy ≥ 8 weeks
• No evidence of active graft-versus-host disease
• Absolute neutrophil count ≥ 1,500/mm³ (no growth factors)
• Platelet count ≥ 75,000/mm³ (transfusion independent)
• Not pregnant or nursing
• Fertile patients must agree to use effective contraception
• Negative pregnancy test
• Hemoglobin ≥ 8 g/dL (may receive RBC transfusions)
• Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT ≤ 2.5 times ULN
• No clinically significant unrelated systemic illness that would preclude study treatment, including any of the following:

• Serious infections
• Hepatic, renal, or other organ dysfunction
• CNS toxicity ≤ grade 2
• No pre-existing sensory or motor neuropathy ≥ grade 2
• Seizure disorder allowed provided it is well controlled by anticonvulsants
• No known prior severe hypersensitivity reaction to agents containing Cremophor EL®
• Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks if prior nitrosourea)
• At least 7 days since prior biologic agents
• At least 2 weeks since prior local palliative (small-port) radiotherapy
• At least 6 months since prior craniospinal radiotherapy OR radiotherapy to ≥ 50% of the pelvis
• At least 6 weeks since other prior substantial bone marrow radiotherapy
• At least 4 months since prior allogeneic stem cell transplant (SCT)
• At least 2 months since prior autologous SCT
• No prior taxane (paclitaxel, docetaxel) therapy
• More than 1 week since prior growth factor use (except epoetin alfa)
• More than 1 week since prior and no concurrent strong inhibitors ofCYP3A4, including any of the following:

• Clarithromycin
• Troleandomycin
• Erythromycin
• Ketoconazole
• Itraconazole
• Fluconazole (doses > 3mg/kg/day)
• Voriconazole
• Nefazodone
• Fluvoxamine
• Verapamil
• Diltiazem
• Amiodarone
• Grapefruit juice
• More than 1 week since prior and no concurrent enzyme-inducing anticonvulsants, including any of the following:

• Carbamazepine
• Felbamate
• Phenobarbital
• Phenytoin
• Primidone
• Oxcarbazepine
• No concurrent aprepitant
• No concurrent Hypericum perforatum (St. John's wort)
• No concurrent sargramostim (GM-CSF) or interleukin-11
• No other concurrent chemotherapy or immunomodulating agents
• No concurrent radiotherapy
• Concurrent steroids allowed for pain or chemotherapy-associated nausea or vomiting

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Brigitte Widemann

Role: PRINCIPAL_INVESTIGATOR

Children's Oncology Group

Locations

Children's Oncology Group

Arcadia, California, United States

Countries

United States

Other Identifiers

NCI-2012-01826

Identifier Type: REGISTRY

Identifier Source: secondary_id

COG-ADVL0524

Identifier Type: -

Identifier Source: secondary_id

CDR0000472912

Identifier Type: -

Identifier Source: secondary_id

NCI-P6451

Identifier Type: -

Identifier Source: secondary_id

NCI-06-C-0146

Identifier Type: -

Identifier Source: secondary_id

ADVL0524

Identifier Type: OTHER

Identifier Source: secondary_id

ADVL0524

Identifier Type: OTHER

Identifier Source: secondary_id

U10CA098543

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2012-01826

Identifier Type: -

Identifier Source: org_study_id

NCT00318526

Identifier Type: -

Identifier Source: nct_alias